BioCentury

Current Editions

December 18, 2024
Tertiary lymphoid structures: Key to predicting and improving cancer immunotherapy response?

At least two companies are preparing to take inducers of tertiary lymphoid structure into the clinic

Product Development

Discovery & Translation

Science Spotlight: Platelets as targeted protein degraders 

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity

Politics, Policy & Law

Finance

Fed forecast could spell cloudy skies for biotech into 2025

Biotech likely to remain under macroeconomic pressure as Fed halves projections for interest rate cuts next year

Management Tracks

Bumpus leaving FDA

Plus: Ra capital names three new partners and updates from Anaveon, Adicet, Bio Usawa and Neopredics

BioCentury ISSN 1097-7201